06 January 2026
06 January 2026
Reporter Ross Law and editors Abigail Beaney and Robert Barrie reflect on a busy 2025, along with discusing forecasts for 2026.
GlobalData analyst Vasilis Roumpelakis notes that bispecifics could hold strong potential in the future, but manufacturing and payer acceptance challenges remain.
Radiopharma specialist Aktis will direct funds towards clinical trials of its most advanced candidates.
The approval from Health Canada was based on data from the Phase III PALISADE study.
The NDA follows positive results from the Phase III global placebo-controlled, randomised VERIFY trial.
Under the terms, Insilico will receive up to $32m in upfront and near-term research payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
